Docetaxel and Cetuximab in Patients With Docetaxel-resistant Hormone-refractory Prostate Cancer (HRPC). A Multicenter Phase II Trial
Latest Information Update: 09 Nov 2021
At a glance
Most Recent Events
- 25 Jun 2012 Actual end date Apr 2010 added as reporetd by ClinicalTrials.gov.
- 25 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.